Paclitaxel and pegylated‐liposomal doxorubicin are both active in angiosarcoma

Skubitz, Keith M.; Haddad, Philip A.

doi:10.1002/cncr.21140

Cited by 187 publications

(116 citation statements)

References 38 publications

(46 reference statements)

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…5 Cutaneous AS is an aggressive neoplasm with a strong propensity to metastasize, most commonly to the liver, breast, lungs, skin, spleen, and bone. 6,7 The overall 5-year survival rate is less than 30%.…”

Section: Discussionmentioning

confidence: 99%

“…The authors found paclitaxel to have unique activity in angiosarcoma of the scalp and face, owing to its angiogenic potential. 7,9 Ono and associates reported partial remission in 2 patients with inoperable cutaneous AS of the scalp treated with sorafenib 400 mg twice daily. Sorafenib, an oral multiple-kinase inhibitor of KIT, FLT-3, VEGFR-1,2,3, and PDGFR-β, leads to a dosedependent reduction in tumor growth.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Untitled

Blackmon

Rajpara

Patel

et al. 2014

Exp Clin Transplant

View full text Add to dashboard Cite

Angiosarcoma is a rare malignant neoplasm of vascular endothelial cells. A majority are primarily in the skin. Angiosarcoma of the head and neck is the most common form, but only constitutes 0.1% of all head and neck malignancies. We present an extraordinary case of a 71 year-old male six months status post orthotopic liver transplant secondary to end stage liver disease from cryptogenic cirrhosis, who presented to the liver clinic with a rapidly growing scalp tumor and hypodense lesions within the liver. Further work-up and biopsies confirmed the first documented case of primary scalp angiosarcoma with metastasis to the liver in an orthotopic liver transplant patient. Case ReportA 71-year-old man with an orthotopic liver transplant 6 months earlier, secondary to end-stage liver disease from cryptogenic cirrhosis, presented to the liver clinic with abdominal distension and worsening ascites. The patient was otherwise asymptomatic and denied having fever, chills, abdominal pain, nausea, vomiting, and diarrhea. For immunosuppression, he had been receiving tacrolimus 2 mg twice daily, with tacrolimus levels between 5 and 8. An ultrasound, followed by a computed tomography scan and magnetic resonance imaging of the abdomen, showed numerous small cystic lesions with peripheral enhancement throughout the liver. These findings led the team to be concerned about liver abscesses (Figure 1). The patient was admitted to the hospital for a further work-up.Piperacillin and tazobactam IV were given as antibiotic therapy, and the patient underwent computed tomography-guided paracentesis, aspiration of cystic fluid, and a core needle liver biopsy. The dermatology department was consulted to evaluate a rapidly enlarging and bleeding scalp lesion, present for 5 weeks. A physical examination revealed a bleeding, firm, indurated nodule on the right temporal scalp, with peripheral purpura and ecchymosis extending down the forehead to the right temple (Figure 2). A satellite skin-colored nodule also was noted posterior to the primary lesion. Biopsy of the primary nodule showed dense, diffuse hemorrhagic proliferation of enlarged pleomorphic, mitotic epithelioid, and spindled CD31+ cells, consistent with the diagnosis of epithelioid angiosarcoma (Figure 3)

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Untitled

Blackmon

Rajpara

Patel

et al. 2014

Exp Clin Transplant

View full text Add to dashboard Cite

show abstract

“…Fata and colleagues reported activity of paclitaxel in face and scalp angiosarcomas with eight patients out of nine achieving either CR or PR [18]. Another agent liposomal doxorubicin appears to be a potent alternative agent particularly for skin angiosarcomas [19,20].…”

Section: Angiosarcomamentioning

confidence: 99%

Systemic Therapy in Soft Tissue Sarcomas: Past, Present and Future

Purohit

Bhise

Appachu

et al. 2011

Indian J Surg Oncol

View full text Add to dashboard Cite

Soft tissue sarcomas (STS) comprise 1% of all cancers diagnosed worldwide with more than 40 different histological subtypes each with distinct underlying biology, natural history and response to treatment. Due to the differential chemosensitivity it is imperative to have a correct histological diagnosis for optimal treatment of these patients. Even though surgery remains the primary modality of treatment there is increasing specialization of chemotherapy with respect to histological subtype. In general there is no place for "one size fits all strategy". To correctly define the role of chemotherapy, an extensive search was carried out online and offline for all relevant articles concerning chemotherapy in soft tissue sarcoma. This review aims to discuss the evolution of chemotherapy, its present role in neoadjuvant, adjuvant, metastatic settings and exciting trends with the advent of targeted therapies.

show abstract

“…The microscopic appearance of angiosarcoma varies from epithelioid to spindled areas, with the former being more common. Various prognostic factors have been reported, including older age, tumor size larger than 5 cm, high grade, positive margin and lymphedema field location [Skubitz KM et al, 2005]. A prospective clinical study with a larger sample size is needed to determine the prognostic factors in angiosarcoma patients.…”

Section: Angiosarcoma Of Head and Neckmentioning

confidence: 99%